Form 4: Halozyme Therapeutics SVP, Chief Technical Officer Michael J. LaBarre Executes Option Exercises and Stock Sales

Michael J. LaBarre, SVP, Chief Technical Officer of Halozyme Therapeutics, executed option exercises and sales of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On May 21 and 22, 2024, Michael J. LaBarre, SVP, Chief Technical Officer of Halozyme Therapeutics, exercised options to purchase 10,000 shares of common stock on each day at a price of $8.11 per share.
• Concurrently, LaBarre sold 10,000 shares of common stock on each day at weighted average prices of $45.164 and $45.384, respectively.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on March 9, 2023.
• Following these transactions, LaBarre directly owns 168,176 shares of common stock and 21,715 derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating routine transactions. The sentiment is neutral as it simply reports facts without expressing any opinion or forward-looking statements.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects.

Comparison to Industry Standards

• Executive compensation packages often include stock options as a way to align management's interests with those of shareholders.
• Rule 10b5-1 trading plans are a standard practice for executives to manage their stock transactions while avoiding insider trading concerns.
• The size and frequency of these transactions are typical for executives at similar-sized biotechnology companies.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased number of shares in the market.

Key Dates